Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Federal Sweep Nets 40 Criminal, Civil Cases For Spiked Supplements, Disease Claims

This article was originally published in The Tan Sheet

Executive Summary

A deputy assistant attorney general clarifies that ongoing investigations target “unlawful makers and marketers of dietary supplements,” but DoJ and other agencies broadly warn the entire industry about the potential for additional criminal cases as well as civil complaints.

You may also be interested in...



Supplement Sector Regulatory Milestones: Senators' Enforcement Push, GNC Supply Chain Guidelines

Former FDA OCI Director George Karavetsos says GNC's supply chain guidelines for its vendors is the industry standard, while Sens. Hatch and Heinrich exceeded all standards by recommending DoJ get tougher on firms violating FDA supplement product regulations,

Naturecom Warned On GMPs After Cooperating On DMAA Recall

FDA warning states Naturecom, which markets its own products and provides ingredients and products to other firms, failed to comply with supplement GMP requirements for master manufacturing and batch production records.

USPlabs' DMAA Supplement Source Convicted In Separate Criminal Case

Federal prosecutors already have cooperation in their case against USPlabs from GNC in exchange for a "non-prosecution" commitment, and might seek help from an executive with S.K. Labs recently convicted on five criminal counts stemming from a separate investigation.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel